H.C. Wainwright Maintains Its Bullish Stance on Vera Therapeutics (VERA), Sees Strong Future Revenue Growth
On November 10, 2025, The Fly reported that H.C. Wainwright increased its price target on Vera Therapeutics, Inc. (NASDAQ:VERA) from $85 to $90, while maintaining a “Buy” rating.
Hedge Fund Resource Center
